# Tisagenlecleucel In Primary CNS Lymphoma

> **NCT04134117** · PHASE1 · COMPLETED · sponsor: **Matthew J. Frigault, M.D.** · enrollment: 13 (actual)

## Conditions studied

- Primary CNS Lymphoma
- Refractory Primary CNS Lymphoma
- Relapsed Primary CNS Lymphoma

## Interventions

- **BIOLOGICAL:** Tisagenlecleucel

## Key facts

- **NCT ID:** NCT04134117
- **Lead sponsor:** Matthew J. Frigault, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2022-04-14
- **Final completion:** 2022-04-14
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04134117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04134117, "Tisagenlecleucel In Primary CNS Lymphoma". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT04134117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*